Cell-to-cell transfer of viral particles through the virological synapse (VS) is a highly efficient mode of HIV-1 transmission. Formation of the VS, a transient multiform adhesion structure, is mediated through an interaction between the HIV-1 envelope glycoprotein (Env) and the viral receptor CD4 on the surface of infected cell and target cell, respectively. Given that Env, unlike many other viral fusogens, can mediate the merger of membranes at neutral pH, the close encounter of infected and uninfected cells would seem prone to result in cell-cell fusion and thus the formation of syncytia. However, while it is being recognized now that small, T cell-based syncytia are indeed a defining feature of the natural history of HIV-1, the majority of VSs nevertheless resolve without fusion, thus securing continued virus spread. Gag, the main viral structural component, is partially responsible for restraining Env and preventing it from becoming fusogenic before being incorporated into particles. In addition, a few cellular factors, including tetraspanins and ezrin, have also been shown to inhibit Env's activity while this fusogen is still part of the producer cell.
Introduction
HIV-1 spreads between T cells primarily through two modes of transmission: the release of cellfree viral particles, and cell-to-cell transmission of particles via the virological synapse (VS). Formation of the HIV-1 VS is initiated by the viral envelope glycoprotein (Env) on the surface of productively infected cells binding to its receptor, CD4, on target T cells (1) , and is followed by polarization of Gag at the cell-cell contact site (1, 2) . Virus particles are then released in high concentrations towards the target cell (3) , facilitating efficient infection while also possibly shielding virus particles from some neutralizing antibodies ((4) and reviewed in (5) ). Given that Env is fusogenic at neutral pH, it may seem likely at first that VS-mediated contacts would frequently result in cell-cell fusion, thus forming a multinucleated infected cell (syncytium). Indeed, we now know that small, T cell based syncytia arise early in HIV-1 infection (6) (7) (8) (9) . However, the majority of infected T cells observed in lymphoid tissue are mononucleated, indicating that most HIV-1 VSs ultimately result in complete cell separation and generation of a new, productively infected cell, likely due to tight regulation that acts to prevent excessive syncytium formation (reviewed in (10) ).
Multiple independent studies have identified viral and host functions which, together, prevent excessive HIV-1-induced cell-cell fusion at the VS. Firstly, Env is rapidly downregulated from the surface of infected cells in the absence of Gag, thus preventing premature Env-mediated membrane fusion (11, 12) . Further, upon Gag multimerization at the plasma membrane, Env is trapped by Gag through Env's cytoplasmic tail and maintained in a non-fusogenic state (13) . This trapping by Gag ends only after Env's incorporation into viral particles, when Gag precursor gets cleaved, i.e. upon maturation (14) (15) (16) (17) . Additionally, several host membrane proteins that accumulate at the producer cell side of the VS, including tetraspanins and ezrin, have been identified as fusion-inhibitory proteins (18) (19) (20) . Tetraspanins inhibit HIV-1-induced cell-cell fusion at a post-hemifusion stage (19) , while ezrin is implicated in F-actin organization and recruitment of tetraspanin CD81 to the VS (20) . It remains unclear how and whether these protein functions are coordinated, though based on other cell-cell fusion regulation paradigms (discussed below), additional host proteins are likely required to mediate efficient inhibition of HIV-1-induced fusion by tetraspanins and ezrin.
EWI-F (CD9P-1/FPRP) is an immunoglobulin superfamily (IgSF) member and partner of tetraspanins CD9 and CD81 (21) . EWI-F was shown to be a potent inhibitor of cell-cell fusion in myoblasts, where EWI-F knockout resulted in more efficient fusion than CD9/CD81 double knockout (22) . However, EWI-F is poorly expressed in T cells (23) , the primary host cell type for HIV-1 infection. Another IgSF member and tetraspanin partner protein which is expressed in T cells (21, 23) , EWI-2 (IGSF8/PGRL) (24, 25) , has been documented to play a role in HCV entry (26, 27) and T cell immunological synapse (IS) formation (28). That latter study -2 has a yet undetermined involvement in HIV-1 particle production (28). Furthermore, both EWI-F and EWI-2 interact with ezrin to organize the cytoskeleton in concert with tetraspanins (23) . EWI-2 thus lies at the nexus of tetraspanins, ezrin, and the actin cytoskeleton (which can also inhibit cell-cell fusion; (29)) and we therefore sought to test whether EWI-2 contributes to the inhibition of HIV-1-induced cell-cell fusion.
Materials and Methods

Cell Lines and Cell Culture
The following cells were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HeLa cells from Dr. Richard Axel (30), TZM-bl cells from Dr. John C. Kappes, Dr. Xiaoyun Wu, and Tranzyme Inc. (31) (32) (33) (34) (35) and CEM-SS cells from Dr. Peter L. Nara (30, 36, 37 μ g/mL streptomycin; Invitrogen). CEM2n, a kind gift from R. Harris (38) , and CEM-SS cells were maintained in RPMI 1640 media (Corning, Cat. #10-104-CV) supplemented with 10% FBS and antibiotics.
Antibodies
Mouse monoclonal antibody (mAb) to EWI-2 (8A12) was a kind gift from Dr. Eric Rubinstein (21) . Mouse mAb to HIV-1 p24 (AG3.0) was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, from Dr. Jonathan Allan (39) . Secondary antibodies were as follows: Alexa Fluor 594-conjugated donkey polyclonal antibody (pAb) to mouse IgG (Invitrogen Cat. #R37115), Alexa Fluor 647-conjugated donkey pAb to mouse IgG (Invitrogen Cat. #A31571), Alexa Fluor 647-conjugated goat pAb to mouse IgG, Alexa Fluor 647conjugated (Invitrogen Cat. #A21235), and Alexa Fluor 488-conjugated donkey pAb to mouse IgG (Invitrogen, Cat. #A21202). Zenon labeling of primary antibodies with either Alexa Fluor 488 or Alexa Fluor 594 was carried out using Zenon Labeling Kits according to the manufacturer's instructions (Molecular Probes, Eugene, OR, Cat. #Z25002 and #Z25007).
Plasmids and Viral Strains
pcDNA3, pCDNA3.1, and pCMV SPORT6 (Invitrogen) were vectors for EWI-2, CD81, and L6 overexpression, respectively. Proviral plasmids pNL4-3 or pNL4-3 Δ Env (KFS) were a kind gift from Dr. Eric Freed (National Cancer Institute, Frederick, MD, USA) (40) . Fluorescent proteintagged proviral plasmids pNL-sfGI and pNL-sfGI Δ Env (9) were kind gifts from Dr. Benjamin Chen (Mount Sinai School of Medicine, New York, NY). Vesicular stomatitis virus glycoprotein (VSV-G) was used to pseudotype viral stocks produced in HEK 293T cells.
2.4
Virus Stocks and Infections
VSV-G-pseudotyped virus stocks of NL4-3, NL4-3 ∆ Env, NL-sfGI, and NL-sfGI ∆ Env were produced in HEK 293T cells transfected with the proviral plasmid and pVSV-G (at 17:3 ratio) using calcium phosphate precipitation. Supernatants were harvested 2 days after transfection, cleared by centrifugation at 2000 rcf for 10 min, filtered, and stored at -80˚C.
To infect CEM2n cells by spinoculation, two million cells were incubated with RPMI/10% FBS containing 90 µL of virus stock (resulting in ~3% of the cells being infected) or medium alone (for uninfected controls), for 20 min at 37 ˚C, followed by centrifugation at 1200 rcf for 2 h at 37˚C. Cell pellets were allowed to recover at 37 ˚C for 15 min, centrifuged at 300 rcf for 2 min, and resuspended in fresh RMPI/10% FBS. Cells were incubated at 37 ˚C, the medium was refreshed 2 days post infection, and the cells were used 1 day later for all subsequent experiments.
To infect CEM-SS cells by shaking, one or two million cells suspended in CO 2 -independent medium (Gibco) supplemented with 10% FBS were mixed with VSV-G-pseudotyped virus stocks and shaken at 220 rpm for 2 h at 37 ˚C. Cells were then washed and plated in fresh RPMI/10% FBS, and used for experiments as described.
2.5
Quantification of EWI-2 accumulation at the VS CEM-SS cells were infected with VSV-G pseudotyped NL4-3 or NL4-3 Δ Env virus by shaking. Two days post infection, uninfected CEM-SS target cells were labeled with CMAC (Invitrogen) according to manufacturer's instructions, mixed with infected cells at a 1:1 or 1:2 ratio (infected:target), seeded onto the microwell of a 35 mm glass-bottom dish (MatTek Corporation, Ashland, MA, Cat. #P35G-1.5-14-C) coated with poly-L-Lysine (Sigma), and incubated at 37˚ C for 3 to 4.5 h. Cells were then chilled on ice and surface-labeled with 1:200 mouse anti-EWI-2 mAb (8A12) in RPMI/10% FBS for 30 min at 4 ˚C. Surface-labeled cells were fixed with 4% PFA in PBS at room temperature for 10 min and blocked and permeabilized overnight with 1% BSA and 0.2% Triton X-100 in PBS (block/perm). All conditions were labeled with Alexa Fluor 647-conjugated anti-mouse secondary pAb in block/perm buffer at 1:500 dilution. NL4-3 and NL4-3 Δ Env-infected conditions were subsequently stained with Alexa Fluor 594 Zenon-labeled anti-p24 AG3.0 mAb, and fixed again with 4% PFA in PBS. Cells were kept in PBS for imaging.
To visualize only producer cell-associated EWI-2 at the VS, 400,000 target TZM-bl cells (which express undetectable levels of EWI-2) were seeded onto the entire surface of a 35 mm glassbottom dish one day prior to co-culture. The next day, 250,000 CEM-SS cells (infected 3 days prior as described above) were added to the glass microwell of the dish. Five hours later, the cells were surface-labeled with 1:200 mouse anti-EWI-2 mAb (8A12; Zenon-labeled with Alexa Fluor 594) in RPMI/10% FBS on ice for 30 min. Cells were subsequently fixed with 4% PFA in PBS and permeabilized with block/perm for 10 min. Cells were kept in PBS for imaging.
Images were acquired on a DeltaVision epifluorescence microscope (GE/Applied Precision, Issaquah, WA, USA) with an Olympus IX-70 base using an Olympus 60× PlanApo 1.42 NA objective and equipped with a CoolSNAP HQ CCD camera (Photometrics). Images were imported into Fiji for analysis following deconvolution and cropping using Softworx software. The VS was identified using the Gag channel and the level of EWI-2 accumulation was determined by measuring its signal intensity at the VS. For Δ Env controls, cell-cell contacts were identified using the brightfield channel and treated analogous to a VS. To determine the level of enrichment at the VS (or cell-cell contact), EWI-2 signal intensity at that site was divided by the average EWI-2 signal at several non-contact sites on the same cell.
Determining surface levels of EWI-2 by microscopy
To compare EWI-2 surface expression between infected and uninfected cells, CEM2n cells were infected with VSV-G-pseudotyped NL-sfGI as described above. Three days post infection, 3 × 10 5 infected cells were plated onto each well of 8-well glass-bottom plates (CellVis, Mountain View, CA, Cat. #C8-1.5H-N) coated with 1:10 poly-L-Lysine in ddH 2 O. Two additional wells were used for uninfected controls. After 2 h of incubation at 37 ˚C, the medium was replaced with ice cold RPMI/10% FBS containing mouse anti-EWI-2 mAb (8A12) at 1:200 dilution for surface labeling, and incubated for 45 min at 4 ˚C. Following the primary antibody incubation, cells were washed with RPMI/10% FBS and fixed with 4% PFA in PBS for 10 min at 4 ˚C, blocked and permeabilized with PBS containing 1% BSA and 100 µg/ml digitonin for 10 min, and incubated with the indicated secondary antibody in PBS containing 1% BSA for 45 min at room temperature. Cells were washed with PBS containing 1% BSA and imaged in PBS. At least 50 fields containing infected cells were selected for each biological replicate and imaged, deconvolved and cropped using the DeltaVision microscope and Softworx software described above. Images were imported into Fiji for analysis. Background fluorescence was determined using uninfected controls only incubated with the secondary antibody and not the primary, and subtracted from all images by adjusting the minimum brightness of each channel. Threshold masks were applied to all images to aid in the visualization of channels containing GFP and Alexa Fluor 594-associated signal for infected cells and EWI-2 surface staining, respectively. Figure 2 is a representative image, without threshold masks, from 3 independent experiments with 2 replicates each.
Determining surface EWI-2 signal on infected cells by flow cytometry
CEM2n cells infected as described above were harvested after three days and incubated in cold PBS with 5 mM EDTA for 15 min (3.0 x 10 5 cells/tube). Cells were pelleted at 400 rcf for 7 min at 4 °C and resuspended in cold RMPI/10% FBS containing mouse anti-EWI-2 mAb (8A12) at 1:200 dilution. After a 45 min incubation at 4 °C, cells were washed with cold RPMI/10% FBS and resuspended in ice cold PBS with 5 mM EDTA. To fix, an equal volume of PBS with 8% PFA was added and samples were incubated on ice for 10 min. Cells were washed and stained with Alexa Fluor 594-conjugated secondary antibody at 1:500 in PBS with 1% BSA for 45 min at room temperature, before being washed, resuspended in PBS, and analyzed using a BD LSRII flow cytometer. Data were analyzed using FlowJo V10 (Becton, Dickinson & Company, Franklin Lakes, NJ). Samples were gated for infected and uninfected populations by GFP expression. EWI-2 WT and EWI-2 low gates were set based in part on controls lacking primary antibody, and in part by adjusting the gates to reflect the number of uninfected EWI-2 WT cells as measured by microscopy. The data shown are the collection of 3 independent biological replicates, each consisting of 2 technical replicates.
HIV-1-induced cell-cell fusion assay
50,000 HeLa cells were plated in each well of a 24-well plate and, the next day, transfected in duplicate or triplicate with 0.1 µg of either pNL-sfGI or pNL-sfGI Δ Env along with 0.5 or 0.625 µg total expression vector carrying the protein of interest (L6, CD81, or EWI-2) using FuGene6 transfection reagent at a ratio of 3:1 (Fugene6:DNA) according to manufacturer's instructions (Promega, Madison, WI, Cat. #E2691). For dose response assays, 0.125, 0.25, or 0.5 µg of the protein expression plasmid of interest was co-transfected with L6 expression plasmid to maintain 0.5 µg of total protein expression plasmid in each condition. For EWI-2 and CD81 cotransfections, 0.5 µg of EWI-2 was co-transfected with 0.125 µg of CD81, while conditions where only either EWI-2 or CD81 was expressed were brought up to 0.625 µg of total overexpression plasmid using L6 as described above. Each transfection condition was performed in duplicate or triplicate. 24 h post-transfection, producer HeLa cells were co-cultured with 10 6 TZM-bl (target; which upon producer-target cell fusion, express firefly luciferase under control of the HIV-1 LTR) cells per well for 3 h before unattached target cells were washed off and the medium was refreshed. 14-18 h later, cells were lysed for at least 30 min on ice using 1% Triton X-100, 2mM EDTA, 50 mM Tris-HCl, 200 mM NaCl, with 1% protease inhibitor cocktail (Millipore Sigma, Darmstadt, Germany, Cat. #P8340). Lysates were precleared by centrifugation at 20,000 rcf for 5 min at 4 °C and stored at -80°C until use for luciferase activity assays.
Each lysate was incubated with an equal volume of firefly luciferase reagent (Promega, Cat. #E1500) for 1 min in a 96-well white-walled plate (ThermoFisher Scientific, Waltham, MA, Cat. #7571) before collecting luminescence signal intensity. Background luminescence was determined using a lysis buffer blank and subtracted from all experimental samples. Luminescence intensity was used as a quantitave measurement of relative HeLa-TZM syncytium formation against the non-fusogenic, Δ Env control. The data shown are the collection of 5 and 2 independent biological replicates, for the dose response and co-transfection assays, respectively.
2.9
Statistical Analysis
All statistical analysis was carried out in GraphPad Prism 7 using student's paired t test as indicated. Values were considered significantly different if p ≤ 0.05.
3.
Results
EWI-2 localizes at the virological presynapse in HIV-1-infected CEM-SS cells
Because EWI-2 is known to associate with ezrin and CD81 (21, 23) , two cellular factors that we have previously found to accumulate at the producer cell side of the VS (20, 41), we first sought to determine whether this protein also localizes to the virological presynapse. CEM-SS cells were infected with (VSV-G-pseudotyped) NL4-3 wt, or NL4-3 Δ Env (virus that does not express Env) and mixed with target CEM-SS cells (labeled with a cytoplasmic dye). Upon imaging with a 60× objective, the VS was identified as clusters of immunolabeled Gag present at producertarget contact sites. Similarly to ezrin and CD81 (20, 41), EWI-2 was observed to co-accumulate with Gag at the VS in an Env-dependent manner (Figure 1A , upper half and inset). EWI-2 signal intensity was ~4-fold enhanced at the VS in lymphocytes infected with NL4-3 WT, while no EWI-2 enrichment was seen at cell-cell contacts in cells infected with NL4-3 Δ Env ( Figure 1B) . To determine whether EWI-2 enrichment at the VS takes place within the infected cell (rather than the apposed uninfected target cell), HIV-1-infected CEM-SS cells were co-cultured with uninfected target TZM-bl cells (which do not have detectable EWI-2 on their surface) and imaged as described above. EWI-2 enrichment was observed at the VS as before ( Figure 1A , bottom half), demonstrating that the observed EWI-2 accumulation in CEM-SS-CEM-SS co cultures takes place at least partially within the producer cell ( Figure 1A) . Together, these results document that producer cell-associated EWI-2 is recruited to the VS during HIV-1 cell-to-cell transmission.
Overall surface levels of EWI-2 are decreased in HIV-1-infected cells
Despite their enrichment at the virological presynapse, the EWI-2 partner proteins CD81 and ezrin are overall downregulated in HIV-1-infected cells (20, 41) . We therefore tested whether surface levels of EWI-2 are similarly decreased in CEM2n cells infected with HIV-1 NL-sfGI, a strain in which superfolder GFP (sfGFP) replaces the Nef gene and Nef expression is restored using an IRES (9) . Uninfected CEM2n cells express surface levels of EWI-2 comparable to uninfected primary CD4 + T cells (unpublished observation), and we chose to utilize a GFP reporter virus rather than immunolabeling Gag after fixation because Gag-negative cells still in the early phase of infection can still exhibit host protein downregulation due to early Nef expression (unpublished observation and reviewed in (42)). HIV-1-infected CEM2n cells adhered to glass-bottom dishes were surface-labeled with EWI-2 primary antibody on ice, and fixed before incubation with Alexa Fluor 594-conjugated secondary antibody. Uninfected and HIV-1 infected cells were imaged with a 60× objective and the resulting images were deconvolved. Threshold masks (not shown) were applied using Fiji to identify infected cells (i.e. GFP-expressing) and levels of EWI-2 that were clearly discernible above background secondary antibody binding were determined using appropriate controls. The presence of EWI-2 on each cell was scored as wild type (WT) or low based on the expression patterns of uninfected controls (representative image shown in Figure 2A ). Scoring showed that, on average across three independent biological replicates, ~65% of uninfected cells had WT surface levels of EWI-2, while only ~25% of infected cells had WT EWI-2 surface levels ( Figure 2B ).
We also sought to quantify the frequency of cells with WT and low EWI-2 surface expression by flow cytometry as a means of high-throughput analysis that would include EWI-2 regulation at all stages of HIV-1 infection. HIV-1 NL-sfGI-infected cells, surface-labeled for EWI-2 and analyzed by flow cytometry, were gated for WT or low levels of EWI-2 (analogous to the thresholding method described above). The mean fluorescence intensity of EWI-2-associated signal was lower within the total population of infected cells compared to that of the uninfected cells ( Figure 2D ). Additionally, these data showed that significantly fewer infected cells (identified as GFP + ) had EWI-2 surface expression than uninfected cells (identified as GFP -) in the same culture ( Figure 2C ). Thus, both the quantitative imaging (Figures 2A and 2B ) and the flow cytometric analysis showed that EWI-2 surface levels, similar to those of CD81 and ezrin, are decreased in HIV-1-infected cells.
EWI-2 overexpression lowers the frequency of HIV-1-induced syncytium formation
Likely through their accumulation at the producer cell side of the VS, the EWI-2 partner proteins CD81 and ezrin repress fusion of infected and uninfected cells, i.e. syncytium formation (18) (19) (20) . Given that EWI-2 also accumulates at the VS (Figure 1) , we thought to test whether it also contributes to the inhibition of HIV-1-induced syncytium formation. NL-sfGI-producing HeLa cells overexpressing either EWI-2, CD81, or L6 (a tetraspanin-like surface protein that does not repress HIV-1-induced cell-cell fusion; (20, 43) ) were co-cultured with uninfected target TZM-bl cells. As a negative control for HIV-1-induced cell-cell fusion, Env-deleted NL-sfGI-expressing HeLa cells were also co-cultured with target TZM-bl cells. HIV-1-induced HeLa-TZM-bl syncytia express firefly luciferase under control of the HIV-1 LTR (18) . After 3 h of co-culture, cells were lysed, the lysates were incubated with luciferase reagent, and luminescence was measured using a microplate reader. Overexpression of increasing amounts of EWI-2 (0.125, 0.25, or 0.5 µg of plasmid) in NL-sfGI-producing cells resulted in robust and dose-dependent decrease of cell-cell fusion (at 0.25 and 0.5 µg of input plasmid), though repression was not as extensive as that observed upon CD81 overexpression ( Figure 3A ).
EWI-2 and CD81 do not act synergistically to repress syncytium formation
EWI-2 is a close relative of another tetraspanin partner protein, EWI-F (CD9P-1), which acts alongside the tetraspanins CD9 and CD81 to inhibit myoblast fusion (22) . Given that, in that study, EWI-F ablation resulted in the hyperfusion phenotype faster than CD81/CD9 silencing, it was speculated that EWI-F may regulate fusion inhibition mediated by the two tetraspanins, though this was not yet tested. Here, we thus sought to analyze if EWI-2 can cooperate with CD81 to repress HIV-1-induced syncytium formation, possibly even in a synergistic manner.
The results of the dose-response curves in Figure 3A were used to determine the amount of either the CD81 or the EWI-2 overexpression plasmid that, when co-transfected with pNL-sfGI, resulted in a moderate (~30%) inhibition of syncytium formation (0.125 and 0.5 μ g, respectively). Should these proteins be able to synergistically repress cell-cell fusion, one would expect that co-transfecting those amounts of each plasmid, alongside HIV-1 pNL-sfGI, should result in an overall inhibition of virus-induced syncytium formation of greater than 60%. As shown, however, in Figure 3B , the combination of the two fusion repressors resulted in an inhibition of syncytium formation of only ~50%. Thus, at least under the experimental conditions used here, EWI-2 and CD81 do not act synergistically.
Discussion
Transient alignment of infected (producer) and uninfected (target) cells allows for very efficient transmission of viral particles. However, because of the presence of viral Env and viral receptors at the surface of producer and target cell, respectively, rather than separating after particle transfer, these cells could also easily fuse with each other, thus forming a syncytium. Various viral and cellular factors have been identified which, together, reduce the likelihood of such syncytium formation, and this study now allows us to add EWI-2 to the list of host factors that repress HIV-1 Env-mediated cell-cell fusion.
Our investigations were prompted partially by two recent reports. In one of those studies, Rubinstein and colleagues documented a role for EWI-F, a close relative of EWI-2, in myoblast fusion regulation (22) . EWI-F was shown to act as fusion repressor in cooperation with the tetraspanins CD9 and CD81. With the other study, (28) showed the presence of EWI-2 at sites of contact between uninfected T cells and T cells stably expressing HIV-1 Env. In separate experiments, HIV-1-infected EWI-2 knockdown cells were also shown to have somewhat increased virus production and the authors mentioned (as data not shown) that this was accompanied by augmented syncytium formation, indicating that EWI-2 could be involved in the regulation of HIV-1-induced membrane fusion. The study did not, however, address the question whether the reported increase in syncytium formation was (potentially) caused by the action of EWI-2 in producer or target cells, though the authors speculated that EWI-2, together with α-actinin, might be active in target cells, there possibly contributing to αactinin's actin bundling activity, thus ultimately inhibiting virus entry/fusion. They explicitly stated, however, that they cannot exclude an involvement of EWI-2 in "subsequent steps of the viral life cycle". Our study now reveals that this is indeed the case: during the late phase of the HIV-1 replication cycle, EWI-2 accumulates on the producer cell side of the VS (Figure 1) , and, the results of experiments shown in Figure 3 reveal that such accumulation at the virological presynapse correlates with decreased syncytium formation. Such EWI-2 accumulation and fusion-inhibiting function at the producer cell side of the VS parallels the activities of tetraspanins that also accumulate at the presynapse (41, 44, 45) , recruited by viral Gag (46) . Also paralleling what we observed for tetraspanins (18) , we found that fusion with uninfected target cells was inhibited by EWI-2 in a dose-dependent manner ( Figure 3A) . While, at first sight, CD81 appears to be a more potent inhibitor of cell-cell fusion than EWI-2, at this point we cannot determine whether this is a consequence of other factors, e.g. the levels of EWI-2 or CD81 achieved upon transfection, or whether the absence of endogenous EWI-2 in HeLa producer cells means that overexpressed EWI-2 is quickly downregulated (unlike CD81). Further investigations are required to appropriately compare the contribution of each fusion inhibitor. Given that EWI-2 associates with the tetraspanins CD9 and CD81 (24, 25, 47) , it would have seemed plausible that EWI-2 and CD81 act synergistically to prevent syncytium formation. As shown in Figure 3B , however, we found that the level of fusion inhibition upon EWI-2 and CD81 co-transfection was lower than the sum of the inhibition by each protein individually, i.e. their fusion inhibitory functions do not even seem to be additive as one would have expected if the two proteins act separately. A possible explanation for the observed result would be that EWI-2 desensitizes cells to fusion inhibition by CD81. Alternatively, synergistic fusion inhibition might require a particular ratio of EWI-2 to CD81 during a narrow time window (when Env triggers cell-cell fusion), something that might not be achieved in a simple cotransfection setting.
Interestingly, and paralleling our findings about tetraspanin expression in HIV-1-infected cells (41, 48) , while EWI-2 accumulates at the virological presynapse, overall this protein is downregulated in infected cells (Figure 2) . Also similar to our tetraspanin data, which were confirmed by an independent study (49) , in a recent proteomics screen (50) EWI-2 was found to be one of the host proteins whose expression is diminished in HIV-1-infected T cells. The combination of these two features, i.e. enrichment during one step of the viral replication cycle (assembly and transmission at the VS) and overall downregulation specifically in infected cells, strongly suggests that a particular host factor plays an important role in virus replication, and given the fusion-preventing functions documented in this study, we certainly think this holds true for EWI-2.
Finally, EWI-2's contribution to repressing the formation of HIV-1-induced syncytia may be relevant mostly because this allows for continued spread of the virus, and also because viral particles produced in syncytia are less infectious than those released from mononucleated infected cells (data not shown). Additionally, the action of this protein along with others could also help the virus, or, rather, HIV-1-infected entities, to evade the host immune response. For instance, simply because syncytia are larger and thus more "visible" than individual infected cells, they may be more prone to be attacked by innate immune cells. In addition, these entities likely have a different surface profile than mononucleated infected cells, similar to how e.g. measles virus-induced syncytia show an upregulation of ligands of activating natural killer cell receptors (51). Thus, fusion repressors such as EWI-2, besides supporting efficient viral spread, probably also help HIV-1 to escape attacks by the human immune system. (A) CEM2n cells were infected with NL-sfGI and surface-labeled for EWI-2, fixed, stained with DAPI (shown in blue) and Alexa Fluor 594-conjugated secondary antibody, and imaged. GFP signal (green) was used to identify infected cells, and EWI-2-associated signal is shown pseudocolored in red. Representative cells are shown. Scale bar = 10 µm. (B) Cells were prepared as in (A) and scored as EWI-2 WT or EWI-2 low. Bars represent the mean percentage of uninfected and infected cells scored as EWI-2 WT from 3 separate experiments. Error bars = standard deviation of the mean (SD). (C) CEM2n cells were infected with NL-sfGI and surfacelabeled for EWI-2, fixed, and stained with Alexa Fluor 647-conjugated secondary antibody, and analyzed on a flow cytometer. Bars represent the average percentage of uninfected and infected cells (within the same tube) that were EWI-2 WT from 3 separate experiments. Error bars = SD. (D) EWI-2 surface expression as measured by mean fluorescence intensity (MFI) of EWI-2associated signal in the same flow cytometry dataset as (C). Lines connect paired data points, i.e. infected cells and uninfected cells (within an infected tube) from the same biological replicate.
Figure Legends
Figure 3. EWI-2 overexpression represses infected-uninfected cell fusion but does not act synergistically with CD81.
(A) HeLa-TZM-bl fusion assays were performed using producer HeLa cells that were cotransfected with either pNL-sfGI Δ Env (ΔEnv) or pNL-sfGI (WT) in combination with either EWI-2 (blue), CD81 (red), or L6 overexpression plasmids. Luminescence readings (across 5 independent biological replicates, each with 2 technical replicates) were divided by the Δ Env condition to obtain the fold increase in fusion, and then normalized to the WT co-transfected with L6 condition (represented by the dashed line). Error bars = SD. (B) Fusion assays were performed as described above using producer HeLa cells co-transfected with WT alongside EWI-2 and CD81, or EWI-2 and CD81 independently. All samples (across 2 independent biological replicates, each with 3 technical replicates) were normalized to Δ Env and then to WT/L6 as above, and values were expressed as a percentage reduction of fusion from WT/L6 (i.e. higher values indicate less fusion). Error bars = SD.
